Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

531 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer.
Piro G, Carbone C, Agostini A, Esposito A, De Pizzol M, Novelli R, Allegretti M, Aramini A, Caggiano A, Granitto A, De Sanctis F, Ugel S, Corbo V, Martini M, Lawlor RT, Scarpa A, Tortora G. Piro G, et al. Among authors: carbone c. Br J Cancer. 2023 Jan;128(2):331-341. doi: 10.1038/s41416-022-02028-6. Epub 2022 Nov 16. Br J Cancer. 2023. PMID: 36385556 Free PMC article.
Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer.
Stefani A, Piro G, Schietroma F, Strusi A, Vita E, Fiorani S, Barone D, Monaca F, Sparagna I, Valente G, Ferrara MG, D'Argento E, Di Salvatore M, Carbone C, Tortora G, Bria E. Stefani A, et al. Among authors: carbone c. Front Oncol. 2022 Oct 27;12:1026020. doi: 10.3389/fonc.2022.1026020. eCollection 2022. Front Oncol. 2022. PMID: 36387232 Free PMC article. Review.
Inflammatory profile in mitochondrial diseases: A cohort study.
Primiano G, Plantone D, Piro G, Carbone C, Sabino A, Sancricca C, Di Nottia M, Carrozzo R, Servidei S. Primiano G, et al. Among authors: carbone c. Eur J Neurol. 2023 Oct;30(10):3409-3410. doi: 10.1111/ene.15962. Epub 2023 Jul 16. Eur J Neurol. 2023. PMID: 37402160 No abstract available.
Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC).
Vita E, Stefani A, Piro G, Mastrantoni L, Cintoni M, Cicchetti G, Sparagna I, Monaca F, Horn G, Russo J, Barone D, Di Salvatore M, Trisolini R, Lococo F, Mazzarella C, Cancellieri A, Carbone C, Larici AR, Mele MC, Pilotto S, Milella M, Tortora G, Bria E. Vita E, et al. Among authors: carbone c. Cancer Immunol Immunother. 2023 Nov;72(11):3803-3812. doi: 10.1007/s00262-023-03533-0. Epub 2023 Sep 5. Cancer Immunol Immunother. 2023. PMID: 37668709 Free PMC article.
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients.
Adamo A, Frusteri C, Pilotto S, Caligola S, Belluomini L, Poffe O, Giacobazzi L, Dusi S, Musiu C, Hu Y, Wang T, Rizzini D, Vella A, Canè S, Sartori G, Insolda J, Sposito M, Incani UC, Carbone C, Piro G, Pettinella F, Qi F, Wang D, Sartoris S, De Sanctis F, Scapini P, Dusi S, Cassatella MA, Bria E, Milella M, Bronte V, Ugel S. Adamo A, et al. Among authors: carbone c. Oncoimmunology. 2023 Sep 14;12(1):2253644. doi: 10.1080/2162402X.2023.2253644. eCollection 2023. Oncoimmunology. 2023. PMID: 37720688 Free PMC article.
Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer.
Agostini A, Guerriero I, Piro G, Quero G, Roberto L, Esposito A, Caggiano A, Priori L, Scaglione G, De Sanctis F, Sistigu A, Musella M, Larghi A, Rizzatti G, Lucchetti D, Alfieri S, Sgambato A, Bria E, Bizzozero L, Arena S, Ugel S, Corbo V, Tortora G, Carbone C. Agostini A, et al. Among authors: carbone c. J Transl Med. 2023 Nov 23;21(1):843. doi: 10.1186/s12967-023-04733-z. J Transl Med. 2023. PMID: 37996891 Free PMC article.
An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer.
Ruta V, Naro C, Pieraccioli M, Leccese A, Archibugi L, Cesari E, Panzeri V, Allgöwer C, Arcidiacono PG, Falconi M, Carbone C, Tortora G, Borrelli F, Attili F, Spada C, Quero G, Alfieri S, Doglioni C, Kleger A, Capurso G, Sette C. Ruta V, et al. Among authors: carbone c. Cell Rep Med. 2024 Feb 20;5(2):101411. doi: 10.1016/j.xcrm.2024.101411. Epub 2024 Feb 6. Cell Rep Med. 2024. PMID: 38325381 Free PMC article.
531 results